Antineoplaston Therapy in Treating Children With Visual Pathway Glioma
Completed · Phase 2
Conditions studied: Visual Pathway Glioma
In brief
RATIONALE: Current therapies for children with visual pathway gliomas, which are not amenable to or have not responded to standard therapy, provide limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment of children with visual pathway gliomas, which are not amenable to or have not responded to standard therapy. PURPOSE: This study is being performed to determine the effects (good and bad) that Antineoplaston therapy has on children with visual pathway gliomas, which are not amenable to or have not responded to standard therapy.
Key facts
- Study ID
- NCT00003477
- Run by
- Burzynski Research Institute
- People needed
- 12
- Starts
- 1996-06-01
- Expected to finish
- 2008-05-01
- Last updated by the study team
- 2017-08-24
Who can join
Age: 1 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Burzynski Clinic — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.